Table 3. Comparison of projected susceptibility to antiretroviral medication in children with and without major protease inhibitor (PI) drug resistance mutations.

Projected susceptibility to antiretroviral drug classes:			With major PI mutations	Without major PI mutations
			Nr (%)	Nr (%)
			n = 32	n = 33	p value
PI:1	LPV/r:	Susceptible	0 (0%)	33 (100%)
		Intermediate	12 (37.5%)	0 (0%)	<0.001
		High	20 (62.5%)	0 (0%)
	DRV/r:	Susceptible	22 (68.8%)	33 (100%)
		Intermediate	10 (31.2%)	0 (0%)	<0.001
	TPV/r:	Susceptible	5 (15.6%)	32 (97.0%)
		Intermediate	27 (84.4%)	1 (3.0%)	<0.001
NNRTI:2	EFV:	Susceptible	16 (51.6%)	19 (57.6%)
		Intermediate	2 (6.5%)	1 (3.0%)	0.77
		High	13 (41.9%)	13 (39.4%)
	ETR:	Susceptible	21 (67.7%)	23 (69.7%)
		Intermediate	10 (32.3%)	10 (30.3%)	1
NRTI:2	ABC:	Susceptible	0 (0%)	2 (6.05%)
		Intermediate	26 (83.9%)	29 (87.9%)	0.22
		High	5 (16.1%)	2 (6.05%)
	AZT:	Susceptible	22 (71.0%)	29 (87.9%)
		Intermediate	5 (16.1%)	3 (9.1%)	0.22
		High	4 (12.9%)	1 (3.0%)
	d4T:	Susceptible	20 (64.5%)	29 (87.9%)
		Intermediate	6 (19.4%)	3 (9.1%)	0.08
		High	5 (16.1%)	1 (3.0%)
	TDF:	Susceptible	22 (71.0%)	30 (90.9%)
		Intermediate	7 (22.6%)	3 (9.1%)	0.08
		High	2 (6.4%)	0 (0%)
	3TC:	Susceptible	2 (6.45%)	3 (9.1%)
		Intermediate	2 (6.45%)	0 (0%)	0.42
		High	27 (87.1%)	30 (90.9%)

Data collected from 65¹ and 64² patients respectively

Predicted drug susceptibility categories were determined through the Stanford HIVdb Algorithm

Abbreviations: PI = protease inhibitors; LPV/r = ritonavir-boosted lopinavir; DRV/r = ritonavir-boosted darunavir; TPV/r = ritonavir-boosted tipranavir; NNRTI = non-nucleoside reverse transcriptase inhibitor; EFV = efavirenz; ETR = etravirine; NRTI = nucleoside reverse transcriptase inhibitor; ABC = abacavir; AZT = zidovudine; d4T = stavudine; TDF = tenofovir; 3TC = lamivudine